ÂÜÀòÂÒÂ×

Nathalie Berthuy currently serves as Clinical Operation Director at GeNeuro SA, overseeing operation activities of the temelimab compound program across multiple clinical trials and indications, including Multiple Sclerosis, Diabetes, Amyotrophic Lateral Sclerosis (ALS), and COVID-19. Previously, at Prexton Therapeutics SA (part of Lundbeck Pharmaceuticals), Nathalie managed early phase studies for foliglurax in Parkinson Disease and healthy volunteers, and conducted a phase II study in Parkinson Disease in the US. Nathalie has extensive experience in managing post-market studies at Medtronic, clinical program management at Novartis and Merck Serono, and clinical project management at Allergan, covering various therapeutic areas and ensuring compliance with industry standards throughout all phases of clinical research.